Cargando…

Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis

Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss of neurological function. The design and synthesis of various altered peptide ligands of immunodominant epitopes of myelin proteins to alter the autoimmune response, is a promising therapeutic approach for MS. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Day, Stephanie, Tselios, Theodore, Androutsou, Maria-Eleni, Tapeinou, Anthi, Frilligou, Irene, Stojanovska, Lily, Matsoukas, John, Apostolopoulos, Vasso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450228/
https://www.ncbi.nlm.nih.gov/pubmed/26082772
http://dx.doi.org/10.3389/fimmu.2015.00136
_version_ 1782373974802432000
author Day, Stephanie
Tselios, Theodore
Androutsou, Maria-Eleni
Tapeinou, Anthi
Frilligou, Irene
Stojanovska, Lily
Matsoukas, John
Apostolopoulos, Vasso
author_facet Day, Stephanie
Tselios, Theodore
Androutsou, Maria-Eleni
Tapeinou, Anthi
Frilligou, Irene
Stojanovska, Lily
Matsoukas, John
Apostolopoulos, Vasso
author_sort Day, Stephanie
collection PubMed
description Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss of neurological function. The design and synthesis of various altered peptide ligands of immunodominant epitopes of myelin proteins to alter the autoimmune response, is a promising therapeutic approach for MS. In this study, linear and cyclic peptide analogs based on the myelin basic protein 83–99 (MBP(83–99)) immunodominant epitope conjugated to reduced mannan via the (KG)(5) and keyhole limpet hemocyanin (KLH) bridge, respectively, were evaluated for their biological/immunological profiles in SJL/J mice. Of all the peptide analogs tested, linear MBP(83–99)(F(91)) and linear MBP(83–99)(Y(91)) conjugated to reduced mannan via a (KG)(5) linker and cyclic MBP(83–99)(F(91)) conjugated to reduce mannan via KLH linker, yielded the best immunological profile and constitute novel candidates for further immunotherapeutic studies against MS in animal models and in human clinical trials.
format Online
Article
Text
id pubmed-4450228
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44502282015-06-16 Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis Day, Stephanie Tselios, Theodore Androutsou, Maria-Eleni Tapeinou, Anthi Frilligou, Irene Stojanovska, Lily Matsoukas, John Apostolopoulos, Vasso Front Immunol Immunology Multiple sclerosis (MS) is a serious autoimmune demyelinating disease leading to loss of neurological function. The design and synthesis of various altered peptide ligands of immunodominant epitopes of myelin proteins to alter the autoimmune response, is a promising therapeutic approach for MS. In this study, linear and cyclic peptide analogs based on the myelin basic protein 83–99 (MBP(83–99)) immunodominant epitope conjugated to reduced mannan via the (KG)(5) and keyhole limpet hemocyanin (KLH) bridge, respectively, were evaluated for their biological/immunological profiles in SJL/J mice. Of all the peptide analogs tested, linear MBP(83–99)(F(91)) and linear MBP(83–99)(Y(91)) conjugated to reduced mannan via a (KG)(5) linker and cyclic MBP(83–99)(F(91)) conjugated to reduce mannan via KLH linker, yielded the best immunological profile and constitute novel candidates for further immunotherapeutic studies against MS in animal models and in human clinical trials. Frontiers Media S.A. 2015-04-07 /pmc/articles/PMC4450228/ /pubmed/26082772 http://dx.doi.org/10.3389/fimmu.2015.00136 Text en Copyright © 2015 Day, Tselios, Androutsou, Tapeinou, Frilligou, Stojanovska, Matsoukas and Apostolopoulos. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Day, Stephanie
Tselios, Theodore
Androutsou, Maria-Eleni
Tapeinou, Anthi
Frilligou, Irene
Stojanovska, Lily
Matsoukas, John
Apostolopoulos, Vasso
Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis
title Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis
title_full Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis
title_fullStr Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis
title_full_unstemmed Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis
title_short Mannosylated Linear and Cyclic Single Amino Acid Mutant Peptides Using a Small 10 Amino Acid Linker Constitute Promising Candidates Against Multiple Sclerosis
title_sort mannosylated linear and cyclic single amino acid mutant peptides using a small 10 amino acid linker constitute promising candidates against multiple sclerosis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450228/
https://www.ncbi.nlm.nih.gov/pubmed/26082772
http://dx.doi.org/10.3389/fimmu.2015.00136
work_keys_str_mv AT daystephanie mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis
AT tseliostheodore mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis
AT androutsoumariaeleni mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis
AT tapeinouanthi mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis
AT frilligouirene mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis
AT stojanovskalily mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis
AT matsoukasjohn mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis
AT apostolopoulosvasso mannosylatedlinearandcyclicsingleaminoacidmutantpeptidesusingasmall10aminoacidlinkerconstitutepromisingcandidatesagainstmultiplesclerosis